Loading…
← CockpitCompetitor Analysis › 1477.HK Ocumension TherapeuticsOpen in the cockpit ↗

Ocumension Therapeutics1477.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Industrials›Miscellaneous Commercial Services
Momentum neutral 55
Mkt cap
$501M
US dollars, full cap
Free float
86%
of shares outstanding
$/day
$184,582
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-12.7 pp
WACC 9.8%
Hurdle
n/a
no reverse DCF
Next earnings
121 days
19 Mar 2027
Close · HKDHK$4.86
1D+0.5%
1W-1.9%
1M+1.2%
3M-6.7%
6M-24.1%
YTD-34.3%
1Y-44.1%
ATR %6.9%
52w lowhigh45.6% off high

What Ocumension Therapeutics does

Employees: 552

Ocumension Therapeutics at a glance

Size Ocumension Therapeutics (1477.HK) is a Hong Kong Industrials company (Miscellaneous Commercial Services) with a market value of $501M, the 743rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$4.86 on 18 Nov 2026.

Performance Over six months the shares fell 24.1%, against -6.6% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 77.5% over the last twelve months (peer median +10.1%); the operating margin is -13.5% (peer median 11.3%).

Valuation It trades at 3.5× enterprise value to sales against a peer median of 3.2× (7th most expensive of 20).

Capital Return on invested capital runs 12.7 points below its cost of capital (9.8% WACC).

Next results Next results expected around 19 Mar 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 941477.HK 79
Six months, rebased to 100: Ocumension Therapeutics against the median of its 20 peers (local-currency closes).

Ocumension Therapeutics financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$1.04BHK$872MHK$452MHK$272MHK$185M
Revenue growth—+93%+66%+47%—
Gross profitHK$482MHK$382MHK$233MHK$150MHK$116M
EBITDAHK$28.7M-HK$17.9M-HK$236M-HK$381M-HK$483M
Net income-HK$142M-HK$172M-HK$291M-HK$420M-HK$468M
Free cash flow-HK$55.4M-HK$138M-HK$219M-HK$259M-HK$336M
Capital expenditureHK$309MHK$275MHK$250MHK$400MHK$360M
Total debtn/aHK$209MHK$27.4MHK$152MHK$33.2M

Quarterly statements and history in the cockpit →

Ocumension Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-10%0%+10%301622MAPMYINDIABTS-B326536367722301456MHA301325300901257530154830086487714290GPI00303230088771990799401477.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Ocumension Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×10×20×30×301622MAPMYINDIABTS-B32653636301325300901257587710030321477.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ocumension Therapeutics is the large dot.

Ocumension Therapeutics competitors and peer comparison

How Ocumension Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ocumension Therapeutics against its 20 peers (data as of 18 Nov 2026)
Measure1477.HKPeer medianRank in peer set
1-month return+1.2%-7.5%5th highest of 21
6-month return-24.1%-6.6%9th lowest of 21
Distance from 52-week high-45.6%-34.2%9th lowest of 21
Revenue growth (TTM)+77.5%+10.1%2nd highest of 21
Operating margin-13.5%11.3%3rd lowest of 21
EV / Sales3.5×3.2×7th most expensive of 20
ROIC minus cost of capital-12.7 pp+3.8 pp3rd lowest of 19
Net debt / EBITDA-9.5×-1.9×2nd least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Ocumension Therapeutics 1477.HKHong Kong$501M-24%+78%-13%3.5×n/an/a
Baotou INST Magnetic New Materials 301622.SZChina$501M-50%+3%-1%2.4×n/an/a
C.E. Info Systems MAPMYINDIA.NSIndia$499M-12%+3%31%8.3×31.7%+25.5%
BTS BTS-B.STSweden$499M+34%0%9%1.9×7.6%+13.0%
Winstek Semiconductor 3265.TWOTaiwan$499M-27%+15%20%3.3×n/an/a
Mitsubishi Research Institute 3636.TJapan$505M+11%+4%7%0.5×-8.6%+4.1%
LINE Pay Taiwan 7722.TWTaiwan$496M+1%+15%6%n/an/an/a
Qingdao Paguld Intelligent Manufacturing 301456.SZChina$494M-32%+29%13%3.2×n/an/a
MHA MHA.LUnited Kingdom$493M-6%+12%15%1.5×-14.9%+30.6%
Shenzhen Manst Technology 301325.SZChina$493M-45%-52%-44%4.8×n/an/a
Zhejiang Zoenn Design 300901.SZChina$512M-24%+53%10%7.0×n/an/a
Xuanzhu Biopharmaceutical 2575.HKHong Kong$514M-60%+237%-187%29.0×n/an/a
Hunan SUND Technological 301548.SZChina$518M-51%+23%21%3.5×16.7%+13.8%
Academy of Environmental Planning & Design Co., Ltd. Nanjing University 300864.SZChina$519M-7%+5%18%3.3×8.9%+10.6%
eGuarantee 8771.TJapan$482M+2%+3%47%5.7×-7.9%+8.3%
Prestige International 4290.TJapan$521M-2%+10%13%0.9×-12.4%+11.8%
GPI GPI.MIItaly$478M+2%+2%6%1.6×n/an/a
Jiangsu Chuanzhiboke Education Technology 003032.SZChina$525M+27%+63%-7%5.8×n/an/a
Pony Testing 300887.SZChina$477M-38%-2%-12%1.9×n/an/a
Premium 7199.TJapan$475M-3%+21%20%0.9×-18.5%+20.6%
Gabia 079940.KSSouth Korea$474M+43%+10%15%1.7×-7.6%+14.7%

Questions

Which companies are Ocumension Therapeutics's closest peers?
The cockpit's peer set: Baotou INST Magnetic New Materials (301622.SZ), C.E. Info Systems (MAPMYINDIA.NS), BTS (BTS-B.ST), Winstek Semiconductor (3265.TWO), Mitsubishi Research Institute (3636.T), LINE Pay Taiwan (7722.TW), Qingdao Paguld Intelligent Manufacturing (301456.SZ), MHA (MHA.L).
Is Ocumension Therapeutics expensive compared with its peers?
On ev / sales it trades at 3.5× against a peer median of 3.2×, 7th most expensive of 20 in its peer set.
How has Ocumension Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned -24.1% against -6.6% for the median peer; over one year -44.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.